Dermasensor Inc.’s elastic scattering spectroscopy device appears to have solved one of the more challenging issues in dermatology—early detection of skin cancers in individuals with darker skin tones. The device demonstrated high sensitivity across all skin cancer types compared to histopathological exams with very little variation between Fitzpatrick skin type groups in an analysis of the DERM-SUCCESS trial.

Renovaro looks to Gedi merger to move on, and advance cancer treatment

Enochian Biosciences Inc. changed its name to Renovaro Biosciences Inc. and reported a deal to merge part of the company with Gedi Cube Intl. Ltd. in an effort to move on from recent controversies. “Renovaro, Latin for ‘renewal,’ represents our company’s mission,” said Mark Dybul, CEO of the company.

Debate over resources for US Medicare administrative functions boils over into plain view

Developers of medical technology have many concerns about the U.S. Centers for Medicare & Medicaid Services’ handling of coverage and reimbursement, but those controversies have typically revolved around process. A new report sponsored by industry steers a somewhat different tack, however, arguing that while there are issues of process, one key issue is that of funding, a problem that only Congress can remedy.

Venostent completes $16M series A financing to aid patients suffering from ESRD

The $16 million will fund a U.S. pivotal trial of bioabsorbable wraps designed to relieve the suffering of patients with end-stage renal disease and in extreme need of hemodialysis to filter toxins from their blood. This comes after developer Venostent Inc. was granted an FDA investigational device exemption in May to begin its Selfwrap-assisted arteriovenous fistula study.

Histoindex’s AI-enabled tissue imaging tech demonstrates consistent results in measuring fibrosis

Histoindex’s artificial intelligence (AI)-enabled tissue imaging technology more accurately measures the change in fibrosis than current pathology tests. With no FDA-approved treatments for nonalcoholic steatohepatitis (NASH), AI can deepen understanding of disease progression and regression as scientists seek effective treatments. The Singapore-based company’s technology is being used in roughly 50% of NASH trials, Histoindex co-founder and CEO Gideon Ho told BioWorld.

Live bacterial biosensor CATCHes tumor DNA in situ

In a study reported in the online edition of Science on Aug. 10, 2023, a group of synthetic biologists from the University of California (UC) San Diego and clinicians from Australia have engineered synthetic bacteria to detect specific DNA sequences in the genomes of colorectal cancer cells and organoids. This living cell sensor capable of detecting cancer in the colons of mice has the potential to steer the way to new biosensors capable of identifying various infections, cancers and other diseases. The study was led by Jeff Hasty, a professor in the UC San Diego School of Biological Sciences and Jacobs School of Engineering, and Daniel Worthley, a gastroenterologist and cancer researcher with the Colonoscopy Clinic in Brisbane, Australia.

Also in the news: 

Synaptive Medical, Shockwave Medical, Ainos, Nisshinbo Micro Devices, Inabata, Bluejay Diagnostics, Imperative Care, Xtant Medical, Dermasensor.